Wall Street Holds Steady Ahead of Fed Decision and Powell’s Speech; GE Vernova Soars
As Wall Street braces for the Federal Reserve's final policy decision of 2025, markets remain in equilibrium. GE Vernova emerges as the S&P 500’s top performer, surging over 90% year-to-date, fueled by ambitious 2026 financial targets. Meanwhile, oil inventories and employment cost data hint at underlying economic trends. Dive into key takeaways, from Amazon’s India expansion to Eli Lilly’s rumored interest in Abivax. --- ### Market Sentiment Ahead of Fed Announcement
U.S. indices hover NEAR equilibrium as investors await the Fed’s rate decision and Jerome Powell’s subsequent remarks. Analysts anticipate a 25-basis-point cut, with the Dow Jones up 0.44% at 47,768 points and the S&P 500 flat at 6,840. The spotlight, however, is on GE Vernova, which skyrocketed 13.47% to $709.51 after unveiling 2026 revenue projections of $41–42 billion—far surpassing 2025 estimates. Its EBITDA margin is also expected to climb to 11–13%, up from 8–9%.
--- ### GE Vernova: The Unstoppable ForceGE Vernova’s meteoric rise reflects investor confidence in its energy-sector dominance. Since January, shares have surged 90%, outpacing peers. The company’s strategic pivot toward renewable energy and grid modernization has resonated, with 2026 targets signaling aggressive growth. "This isn’t just a rally; it’s a validation of their long-term vision," notes a BTCC analyst.
--- ### Macroeconomic Indicators: Mixed SignalsThe U.S. Employment Cost Index ROSE 0.8% in Q3 2025, slightly below forecasts. Oil inventories tell a divergent story: crude stocks fell by 1.812 million barrels last week, while gasoline reserves grew by 6.397 million barrels. Such volatility underscores the Fed’s delicate balancing act.
--- ### Stocks to WatchAmazon’s $35 Billion India Bet
Amazon plans to invest $35 billion in India by 2030, focusing on AI-driven digitization, exports, and job creation. This MOVE aligns with India’s booming tech sector and could redefine e-commerce in the region.
Eli Lilly’s Rumored Abivax Bid
Eli Lilly may be eyeing French biotech Abivax (+9.71%), per Reuters. Abivax’s stock has soared 1,453% this year, fueled by breakthrough therapies—a tantalizing target for Lilly’s pipeline expansion.
GameStop’s Earnings Miss
GameStop’s Q3 revenue slid 4.6% to $821 million, missing estimates. Despite a net profit of $77.1 million, its reliance on physical retail remains a drag in a digital-first era.
--- ### Leadership Shakeup at HoneywellHoneywell appointed Indra Nooyi, former PepsiCo CEO, as independent director effective January 2026. Her track record in scaling global brands could bolster Honeywell’s industrial-tech ambitions.
--- ### FAQ SectionKey Questions Answered
Why is GE Vernova outperforming the S&P 500?
GE Vernova’s 2026 financial targets—$41–42 billion revenue and 11–13% EBITDA margin—exceed expectations, driving investor optimism.
What’s driving Amazon’s India investment?
India’s tech growth and Amazon’s focus on AI, exports, and employment underpin its $35 billion commitment.
Is Abivax a takeover target?
Eli Lilly’s rumored interest stems from Abivax’s stellar YTD performance (+1,453%) and innovative therapies.
